Therapeutic drug monitoring of adalimumab in inflammatory bowel disease in children
| Autor: | T.V. Radygina, A.S. Illarionov, A.S. Potapov, M.G. Vershinina, A.P. Fisenko, S.V. Petrichuk, D.G. Kuptsova, A.N. Surkov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Voprosy detskoj dietologii. 19:14-25 |
| ISSN: | 2414-9519 1727-5784 |
| Popis: | Objective. To evaluate the significance of therapeutic drug monitoring of adalimumab (ADA) concentration levels and antibodies to it in inflammatory bowel disease (IBD) in children. Patients and methods. In this study, 103 children with IBD (24 patients with ulcerative colitis (UC) and 79 with Crohn’s disease (CD)) aged 3–18 years were examined during maintenance therapy with ADA (100 mg/mL in 0.4 mL). Body weight, duration of disease and therapy, use of azathioprine (AZA), achievement of clinical and endoscopic remission, albumin levels, residual levels of ADA and antibodies to the drug, circulating cytokine levels in serum were assessed. Results. A significant decrease in ADA levels in children in the absence of clinical remission in CD (5.21 [3.32; 7.43] μg/mL in remission) and in UC (2.42 [0.42; 4.51] μg/mL, p = 0.001) was shown. A high-quality separation model for residual ADA levels for exacerbation/remission conditions for clinical and endoscopic activity for children with CD and UC was obtained through ROC-analysis. The minimum residual ADA levels for maintaining clinical remission in children with CD were 8.1 μg/mL and 10.5 μg/mL for mucosal healing. In children with UC, as well as in children weighing |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|